Ladenburg lowered the firm’s price target on Celsius Holdings (CELH) to $58 from $62 and keeps a Buy rating on the shares. The new target ...

Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced that it ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Teacher Retirement System of Texas lifted its position in Edison International (NYSE:EIX – Free Report) by 242.0% during the fourth quarter, according to its most recent 13F filing with the SEC. The ...

Operator: Ladies and gentlemen, thank you for standing by. Good afternoon, and welcome to the STRATA Skin Sciences, Inc.

Biotherapeutics has entered into a definitive securities purchase agreement with a single institutional investor for the purchase ...

Stock analysts at Zacks Research lowered their Q3 2026 EPS estimates for shares of Spire in a report issued on Monday, March 24th. Zacks Research analyst R. Department now expects that the utilities ...

Thank you for standing by and welcome to the Corvus Pharmaceuticals fourth-quarter and full-year 2024 business update and financial results conference call. (Operator Instructions) It is now my ...

Calidi Biotherapeutics (NYSE American: CLDI) , a clinical-stage biotechnology company advancing targeted immunotherapies, has entered into a securiti ...

ConferenceHeidelberg Pharma to Present Data from its ADC Technology Platforms at AACR Annual Meeting 2025 26.03.2025 / 09:23 CET/CESTThe issuer is solely responsible for the content of this ...

Ladenburg Income& Growth Fund earns an Average Process Pillar rating. The most substantial contributor to the rating is the firm's retention rate of the firm's portfolio managers, which is 100% ...

Discover Corvus Pharmaceuticals' Q4 2024 earnings insights, highlighting soquelitinib's trial progress, upcoming milestones for 2025, and robust ...